个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 卓越：重点期刊

作者：
Li Ping[1] ; Liu Yang[2] ; Liang Yun[3] ; Bo Jian[4] ; Gao Sujun[5] ; Hu Yongxian[6] ; Hu Yu[7] ; Huang He[6] ; Huang Xiaojun[8] ; Jing Hongmei[9] ; Ke Xiaoyan[9] ; Li Jianyong[10] ; Li Yuhua[11] ; Liu Qifa[12] ; Lu Peihua[13] ; Mei Heng[7] ; Niu Ting[14] ; Song Yongping[15] ; Song Yuqin[16] ; Su Liping[17] ; Tu Sanfang[11] ; Wang Jianxiang[18] ; Wu Depei[19] ; Wang Zhao[20] ; Xu Kailin[21] ; Ying Zhitao[16] ; Yang Qingming[2] ; Zhang Yajing[2] ; Shi Fengxia[2] ; Zhang Bin[22] ; Zhang Huilai[23] ; Zhang Xi[24] ; Zhao Mingfeng[25] ; Zhao Weili[26] ; Zhao Xiangyu[8] ; Huang Liang[27] ; Zhu Jun[16] ; Qian Wenbin[3] ; Han Weidong[2] ; Liang Aibin[1] ;
机构： [1]Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China. [2]Department of Bio-therapeutic, Chinese PLA General Hospital, Beijing 100853, China. [3]Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, China. [4]Department of Hematology, Chinese PLA General Hospital, Beijing 100853, China. [5]Department of Hematology, The First Hospital of Jilin University, Changchun 130012, China. [6]Center for Bone Marrow Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China. [7]Institute of Hematology, Union Hospital of Tongji Medical College [8]Huazhong University of Science and Technology, Wuhan 430022, China. [8]Peking University People's Hospital &amp [10]Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 100044, China. [9]Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, China. [10]Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China. [11]Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, China. [12]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. [13]Lu Daopei Institute of Hematology, Beijing 101102, China. [14]Department of Hematology, West China Hospital, Sichuan University, Chengdu 610041, China. [15]The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China. [16]Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China. [17]Department of Hematology, Shanxi Cancer Hospital, Taiyuan 030013, China. [18]State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Division of Pediatric Blood Disease Center, Institute of Hematology &amp [21]Blood Disease Hospital, Chinese Academy of Medical Sciences &amp [22]Peking Union Medical College, Tianjin 300020, China. [19]Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, Suzhou 215006, China. [20]Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China. [21]Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, China. [22]Institute of Blood and Marrow Transplantation, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100039, China. [23]Department of Lymphoma, Tianjin Medical University Cancer Institute &amp [28]Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China. [24]Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing 400037, China. [25]Department of Hematology, Tianjin First Central Hospital, Tianjin 300192, China. [26]Department of Hematology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. [27]Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
出处：
DOI： 10.20892/j.issn.2095-3941.2022.0585
ISSN：

摘要：
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.Copyright © 2023 Cancer Biology & Medicine.

基金：
This work was supported by funds from the National Natural Science Foundation of China (Grant Nos. 81830002, 81830004, 82070168, and 32070951), the Translational Research grant of NCRCH (Grant No. 2020ZKZC04), and National Key R&D Program of China (Grant No. 2021YFA1100800).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 3 区 医学：研究与实验 3 区 肿瘤学
最新[2023]版：
大类 | 2 区 医学
小类 | 3 区 医学：研究与实验 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY
最新[2023]版：
Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China.
推荐引用方式(GB/T 7714)：
Li Ping,Liu Yang,Liang Yun,et al.2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma[J].CANCER BIOLOGY & MEDICINE.2023,20(2):129-146.doi:10.20892/j.issn.2095-3941.2022.0585.
APA：
Li Ping,Liu Yang,Liang Yun,Bo Jian,Gao Sujun...&Liang Aibin.(2023).2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.CANCER BIOLOGY & MEDICINE,20,(2)
MLA：
Li Ping,et al."2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma".CANCER BIOLOGY & MEDICINE 20..2(2023):129-146

资源点击量：53094 今日访问量：0 总访问量：4588 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号